Literature DB >> 32555425

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.

Priscilla K Brastianos1, Eudocia Quant Lee2, Justine V Cohen3, Sara M Tolaney2, Nancy U Lin2, Nancy Wang3, Ugonma Chukwueke2, Michael D White3, Naema Nayyar3, Albert Kim3, Christopher Alvarez-Breckenridge3, Ian Krop2, Maura Keeley Mahar3, Mia S Bertalan3, Brian Shaw3, Joana L Mora3, Nathaniel Goss3, Megha Subramanian3, Lakshmi Nayak2, Jorg Dietrich3, Deborah A Forst3, Brian V Nahed3, Tracy T Batchelor3, Helen A Shih3, Elizabeth R Gerstner3, Beverly Moy3, Donald Lawrence3, Anita Giobbie-Hurder2, Scott L Carter2, Kevin Oh3, Daniel P Cahill3, Ryan J Sullivan3.   

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Entities:  

Year:  2020        PMID： 32555425     DOI： 10.1038/s41591-020-0978-1

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  3 in total

1.  A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis.

Authors:  Wonyoung Choi; Youngnam Cho; Seog-Yun Park; Kum Hui Hwang; Ji-Youn Han; Youngjoo Lee
Journal:  J Cancer Res Clin Oncol       Date:  2020-07-23       Impact factor: 4.553

Review 2.  Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Authors:  Ajay Dhakal; Amanda E D Van Swearingen; Ruth O'Regan; Carey K Anders
Journal:  Curr Treat Options Oncol       Date:  2022-09-22

Review 3.  [Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer].

Authors:  Naisheng Gao; Tao Xin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.